Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)
      Google Scholar   
Citation:
J Clin Oncol vol 39 (6_suppl) 154
Meeting Instance:
ASCO GU 2021
Year:
2021
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
Yes
Parents:
None
Children:
3697  
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U10CA180882; DOD grant W81XWH-18-1-0278; U24CA196171  
Corr. Author:
 
Authors:
                     
Networks:
LAPS-MA036, LAPS-NC010, LAPS-NY016   
Study
CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: